Former US congressman Dana Rohrabacher has joined a Colombia-based publicly traded marijuana company as an advisor.
David Attard, CEO of the company, said in a release that the firm is angling for an entry to the US market by way of cannabidiol (CBD) products.
The executive added that Rohrabacher will serve the company’s US interests thanks to his experience and understanding of the legislative environment in the country.
Rohrabacher said that, after visiting the facilities of the company, he’s “very engaged” in wanting to help the firm navigate US federal and state policy.
Demand and sales for CBD products in the US have grown exponentially following the legalization of hemp and its derivatives.
This regulatory change has led to a race of producers for novelty products using CBD in the health and wellness market.
Investors have gained a variety of options for plays in the CBD craze, especially with the entrance of established retail pharmacies such as CVS Pharmacy (NYSE:CVS) and Walgreens Boots Alliance (NASDAQ:WBA).
“Our team has received accelerated interest from players in several legal US states in recent weeks as the legal structure of medicinal cannabis continues to evolve across the country,” Attard said.
Shares of PharmaCielo were on the rise during Wednesday’s trading session. The company finished the day at a price of C$6.92, representing a 1.17 percent increase in value.
Rohrabacher, a GOP representative, lost his seat in Orange County, California, during the 2018 midterm elections to Democrat Harley Rouda.
He told Cannabis Now in April that he expects to see more involvement from US President Donald Trump regarding the legalization of marijuana in the run up to the 2020 election.
“I think it will all come down to who the nominee is for the Democratic Party,” he said. “If it’s (Joe) Biden, and then we have President Trump talking about being the person that wants to liberalize marijuana laws.”
During his 30 year run in Congress, Rohrabacher was a vocal advocate for cannabis policies and most famously sponsored an amendment to prevent the justice department from pursuing marijuana businesses in legal states with federal funding.
The Rohrabacher-Farr amendment was turned into law in December 2014.
Special hirings of politicians in the cannabis market have become a trend in the space, with fellow Colombian company Khiron Life Sciences (TSXV:KHRN,OTCQB:KHRNF) adding former Mexican president Vicente Fox to its board of directors.
PharmaCielo reached the Canadian public markets in January when it completed a reverse takeover to list on the TSX Venture Exchange.
As part of its Q1 2019 financial results, the company pointed to the reverse takeover as the cause of its C$7.7 million net loss during the quarter.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Editorial Disclosure: Acreage Holdings and Khiron Life Sciences are clients of the Investing News Network. This article is not paid-for content.
Agreement propels development of safe and effective proprietary products and formulations for the emerging psychedelic industry
Optimi Health Corp. (CSE: OPTI) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that effective January 4, 2021, it entered into a lab services agreement with Numinus Wellness Inc. (“Numinus“). Recognized as an early leader in developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), Numinus is aiding Optimi’s mission to further the research and development of Canadian-grown psilocybin-producing mushrooms and related product formulations.
Nextleaf Solutions Provides a Corporate Update and Comments on Financial Results from the First Quarter
Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), the world’s most innovative cannabis processor, is pleased to provide shareholders with the following corporate update:
Nextleaf Comments on Financial Results from Q1 Financials
Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”) reported its second quarter results for the period ended December 31, 2020. A complete set of financial statements and Management’s Discussion & Analysis has been filed at www.sedar.com. All dollar figures are quoted in Canadian dollars.
The second quarter of FY21, saw continued momentum for the Company despite ongoing pandemic related challenges. Net revenue grew 8% to $745,748 from $689,276 versus the same quarter year ago. The Company also saw significant improvement on its bottom line, reducing its net loss by 50% from ($.956) million to ($.481) million, year over year for the quarter, as a result of improved gross margin and cost management efforts. On December 9, 2020, the company announced the closing of the acquisition of substantially all of the assets of Lexaria Canpharm (“Canpharm“), the cannabis products division of Lexaria Biosciences, resulting in the addition of a new B2B Line of Business.
FinCanna Capital – The Only Publicly Traded, Royalty-Focused Company for the Licensed U.S. Cannabis Industry Provides Corporate Update
Royalty Model Provides Access to Early Stage Licenced U.S. Cannabis Companies and Leverage to High-Margin Revenues
FinCanna Capital Corp. (“FinCanna” or the “Company”) (CSE:CALI), a royalty company for the licensed U.S. cannabis industry, is pleased to provide a corporate update further to its recently announced upsized financing of $2 million
Significant progress made as Numinus-sponsored PRIME study on psilocybin-assisted psychotherapy for opioid, stimulant and/or alcohol use disorders enters pre-implementation stage
Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), and Syreon Corporation (Syreon), a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant progress has been made in the single-arm, open-label compassionate access 1 trial of Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders. Currently in the development stage, the PRIME study will assess the efficacy and safety of psilocybin-assisted motivational enhancement therapy.